A New Combination Chemotherapy for Resistant Hodgkin Disease FREE

Vincent Vinciguerra, MD; Morton Coleman, MD; Charles I. Jarowski, MD; Thomas J. Degnan, MD; Richard T. Silver, MD

[+] Author Affiliations

Reprint requests to Division of Hematology-Oncology, The New York Hospital-Cornell Medical Center, 525 E 68th St, New York, NY 10020 (Dr Coleman).

JAMA. 1977;237(1):33-35. doi:10.1001/jama.1977.03270280035017

Text Size: A A A

Published online

Article

References

ABSTRACT

ABSTRACT | REFERENCES

A new four-drug combination chemotherapeutic regimen (BVDS) was used in the treatment of advanced Hodgkin disease resistant to MOPP (mechlorethamine hydrochloride, vincristine sulfate, procarbazine hydrochloride, and prednisone). The BVDS regimen, consisting of 12 cycles of bleomycin sulfate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and streptozocin (streptozotocin), was administered to ten patients. Responses were seen in five (50%) of these patients. Complete remissions occurred in three (30%). These results suggest that BVDS is an effective alternative regimen to MOPP, and may be of benefit not only to patients resistant to MOPP, but also to newly-diagnosed patients with advanced Hodgkin disease when combined sequentially with MOPP.

(JAMA 237:33-35, 1977)

REFERENCES

ABSTRACT | REFERENCES

DeVita VT: Combined drug treatment of Hodgkin's disease: Remission induction, remission duration, and survival; an appraisal . Natl Cancer Inst Monogr 36:373-379, 1973;.

Frei E, Luce JK, Gamble JF, et al: Combination chemotherapy in advanced Hodgkin's disease . Ann Intern Med 79:376-382, 1973;.

Goldsmith MA, Carter SK: Combination chemotherapy of advanced Hodgkin's disease . Cancer 33:1-8, 1974;.

DeVita V, Canellos G, Hubbard S, et al: Chemotherapy of Hodgkin's disease: A 10 year progress report , abstracted. Proc Am Soc Clin Oncol 17:269, 1976;.

Blum RH, Carter SK, Agee K: A clinical review of bleomycin—a new antineoplastic agent . Cancer 31:903-914, 1973;.

Carter S, Livingston R: Single agent therapy of Hodgkin's disease . Arch Intern Med 131:377-387, 1973;.

Blum RH, Carter SK: Adriamycin—a new anticancer drug with significant clinical activity . Ann Intern Med 80:249-259, 1974;.

Schein P, O'Connell M, Blum J, et al: Clinical antitumor activity and toxicity of streptozotocin . Cancer 34:993-1000, 1974;.

Chang P, Riggs C, Reich SD, et al: Aggravation of adriamycin toxicity by streptozotocin: Clinical-pharmacologic correlation , abstracted. Proc Amer Soc Clin Oncol 17:298, 1976;.

Streiff R, Corley C, Brown M, et al: Education Program Booklet of the 17th Annual Meeting . Atlanta, Ga, American Society of Hematology, 1974;, p 5.

Vinciguerra VP, Coleman M, Degnan RJ, et al: Combination chemotherapy for MOPP-resistant Hodgkin's disease (BVDS) , abstracted. Clin Res 23:284, 1975;.

Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP . Cancer 36:252-259, 1975;.

Vincente J, Cortes Funes H: ABVD for the treatment of advanced resistant lymphoma , abstracted. Proc Am Soc Clin Oncol 17:189, 1976;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal